RU2019121992A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019121992A3 RU2019121992A3 RU2019121992A RU2019121992A RU2019121992A3 RU 2019121992 A3 RU2019121992 A3 RU 2019121992A3 RU 2019121992 A RU2019121992 A RU 2019121992A RU 2019121992 A RU2019121992 A RU 2019121992A RU 2019121992 A3 RU2019121992 A3 RU 2019121992A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
- A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
- C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Nanotechnology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Optics & Photonics (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662434344P | 2016-12-14 | 2016-12-14 | |
| US62/434,344 | 2016-12-14 | ||
| US201762443567P | 2017-01-06 | 2017-01-06 | |
| US201762443522P | 2017-01-06 | 2017-01-06 | |
| US62/443,522 | 2017-01-06 | ||
| US62/443,567 | 2017-01-06 | ||
| US201762517346P | 2017-06-09 | 2017-06-09 | |
| US62/517,346 | 2017-06-09 | ||
| PCT/US2017/066541 WO2018112278A1 (en) | 2016-12-14 | 2017-12-14 | Methods and compositions for nucleic acid and protein payload delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019121992A RU2019121992A (ru) | 2021-01-15 |
| RU2019121992A3 true RU2019121992A3 (cg-RX-API-DMAC7.html) | 2021-01-26 |
Family
ID=62488586
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019121801A RU2019121801A (ru) | 2016-12-14 | 2017-12-14 | Композиции и способы для доставки полезной нагрузки в виде нуклеиновой кислоты и/или белка |
| RU2019121992A RU2019121992A (ru) | 2016-12-14 | 2017-12-14 | Способы и композиции для доставки полезной нагрузки в виде нуклеиновых кислот и белков |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019121801A RU2019121801A (ru) | 2016-12-14 | 2017-12-14 | Композиции и способы для доставки полезной нагрузки в виде нуклеиновой кислоты и/или белка |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US10975388B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3554555A4 (cg-RX-API-DMAC7.html) |
| JP (4) | JP2020502124A (cg-RX-API-DMAC7.html) |
| KR (4) | KR20240027888A (cg-RX-API-DMAC7.html) |
| CN (2) | CN110582302A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017378431A1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3045131A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL267034B2 (cg-RX-API-DMAC7.html) |
| RU (2) | RU2019121801A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2018112278A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210069016A1 (en) * | 2008-11-13 | 2021-03-11 | Gholam A. Peyman | Neurodegenerative Disorder Treatment Method |
| CA3049980A1 (en) | 2017-01-23 | 2018-07-26 | Regeneron Pharmaceuticals, Inc. | Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof |
| CA3059348A1 (en) | 2017-04-11 | 2018-10-18 | Regeneron Pharmaceuticals, Inc. | Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (hsd17b) family |
| MY200418A (en) | 2017-06-15 | 2023-12-25 | Univ California | Targeted non-viral dna insertions |
| KR102712142B1 (ko) | 2017-07-31 | 2024-10-07 | 리제너론 파마슈티칼스 인코포레이티드 | Cas-형질전환 마우스 배아 줄기 세포 및 마우스 및 이것의 용도 |
| CN111182790A (zh) | 2017-07-31 | 2020-05-19 | 瑞泽恩制药公司 | Crispr报告体非人类动物及其用途 |
| AU2018348195B2 (en) | 2017-10-11 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation |
| SG11202003798TA (en) | 2017-10-27 | 2020-05-28 | Univ California | Targeted replacement of endogenous t cell receptors |
| EP3592140A1 (en) | 2018-03-19 | 2020-01-15 | Regeneron Pharmaceuticals, Inc. | Transcription modulation in animals using crispr/cas systems |
| MY207352A (en) | 2018-03-21 | 2025-02-21 | Regeneron Pharma | 17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof |
| US20200149070A1 (en) * | 2018-04-24 | 2020-05-14 | Ligandal, Inc. | Methods and compositions for genome editing |
| WO2020051396A1 (en) * | 2018-09-08 | 2020-03-12 | Blueallele, Llc | Methods and compositions for modifying the von willebrand factor gene |
| US12534728B2 (en) | 2018-09-19 | 2026-01-27 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of 17beta-HSD type 13 (HSD17B13), compositions thereof, and methods of use |
| CN113423834A (zh) * | 2018-11-08 | 2021-09-21 | 加总生物公司 | 微核小体核心蛋白及其在核酸递送中的用途 |
| CN113195003B (zh) | 2018-11-30 | 2024-12-31 | 国立大学法人京都大学 | 使用溶液的药物递送系统 |
| CN119193710A (zh) * | 2018-12-05 | 2024-12-27 | 弗莱德哈钦森癌症中心 | 遗传修饰细胞的减少和最少的操作制造 |
| WO2020131862A1 (en) * | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Crispr-associated transposase systems and methods of use thereof |
| US11249941B2 (en) * | 2018-12-21 | 2022-02-15 | Palo Alto Research Center Incorporated | Exabyte-scale data storage using sequence-controlled polymers |
| CN111363013B (zh) * | 2018-12-25 | 2021-11-19 | 深圳先进技术研究院 | 多组分纳米颗粒簇的构建方法 |
| CN109735540B (zh) * | 2019-01-22 | 2022-05-31 | 南京鼓楼医院 | SH2D1A基因、sgRNA及其应用 |
| US20210379192A1 (en) * | 2019-01-25 | 2021-12-09 | Mantra Bio, Inc. | Skeletal muscle targeting moieties and uses thereof |
| MA55082A (fr) | 2019-03-01 | 2022-01-05 | Flagship Pioneering Innovations Vi Llc | Compositions, procédés, et kits pour l'administration de polyribonucléotides |
| KR102901623B1 (ko) | 2019-03-01 | 2025-12-18 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 폴리리보뉴클레오티드 및 이의 미용적 용도 |
| CA3138991A1 (en) * | 2019-05-02 | 2020-11-05 | Ligandal, Inc. | Methods and compositions for diagnostically-responsive ligand-targeted delivery of therapeutic agents |
| MX2022000045A (es) | 2019-06-26 | 2022-04-20 | Biorchestra Co Ltd | Nanoparticulas micelares y sus usos. |
| JP7630904B2 (ja) * | 2019-07-23 | 2025-02-18 | 株式会社東芝 | 核酸導入キャリア、核酸導入キャリアセット、核酸導入組成物及び核酸導入方法 |
| CN110628723B (zh) * | 2019-09-05 | 2021-05-04 | 清华大学 | 基因修饰MSCs治疗2型糖尿病 |
| US20210163935A1 (en) * | 2019-09-05 | 2021-06-03 | Trevor P. Castor | Targeted Critical Fluid Nanoparticles Platform for Delivery of Nucleic Acids for Treatment of HIV-1 and Other Diseases |
| US12521451B2 (en) | 2019-11-08 | 2026-01-13 | Regeneron Pharmaceuticals, Inc. | CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy |
| CN112779317A (zh) * | 2019-11-11 | 2021-05-11 | 香港中文大学深圳研究院 | 一种用于小分子核糖核酸检测的试剂及其应用 |
| US20230248658A1 (en) * | 2019-11-15 | 2023-08-10 | The Regents Of The University Of California | Supramolecular nanosubstrate-mediated delivery system enables crispr/cas9 knockin of hemoglobin beta gene-a potential therapeutic solution for hemoglobinopathies |
| US12663345B2 (en) | 2020-01-13 | 2026-06-23 | Illumina, Inc. | Devices for generating monodisperse droplets from a bulk liquid |
| JP2023511279A (ja) | 2020-01-13 | 2023-03-17 | フルーエント バイオサイエンシーズ インコーポレイテッド | 単一細胞シーケンシング |
| JP7562682B2 (ja) | 2020-01-27 | 2024-10-07 | マントラ バイオ,インコーポレイテッド | キメラ小胞局在化部分を含む非天然発生の小胞、その産生方法、およびその使用 |
| KR20220158723A (ko) * | 2020-02-25 | 2022-12-01 | 리간달 인코포레이티드 | 생체모방 바이러스 펩티드의 확인 및 그의 용도 |
| WO2021168575A1 (en) * | 2020-02-27 | 2021-09-02 | Quadrumix Biotechnology Inc. | Polypeptides directed against viral infection and uses thereof |
| CA3175931A1 (en) | 2020-03-16 | 2021-09-23 | Fluent Biosciences Inc. | Multi-omic analysis in monodisperse droplets |
| US12428685B2 (en) | 2020-03-24 | 2025-09-30 | Illumina, Inc. | Viral detection using template emulsification |
| EP4136235A4 (en) * | 2020-04-13 | 2024-10-16 | Summation Bio, Inc. | MINI-NUCLEOSOME CORE PROETIN AND THEIR USE IN NUCLEIC ACID DELIVERY |
| IL298363A (en) | 2020-05-20 | 2023-01-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions and uses thereof |
| CA3189597A1 (en) | 2020-07-15 | 2022-01-20 | Fluent Biosciences Inc. | Tiered ligation oligos |
| CN111968707B (zh) * | 2020-08-07 | 2022-06-17 | 上海交通大学 | 基于能量的原子结构与电子密度图多目标优化拟合预测方法 |
| CN111888333A (zh) * | 2020-08-11 | 2020-11-06 | 深圳大学 | 一种转铁蛋白受体靶向的纳米胶束及其制备方法与应用 |
| CN116685357A (zh) * | 2020-08-21 | 2023-09-01 | 利甘达尔股份有限公司 | 纳米颗粒种子底物的组合物和方法 |
| IL300947A (en) | 2020-09-03 | 2023-04-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions and uses thereof |
| WO2022144811A1 (en) * | 2020-12-30 | 2022-07-07 | Biorchestra Co., Ltd. | Micellar nanoparticles and uses thereof |
| WO2022144812A1 (en) * | 2020-12-30 | 2022-07-07 | Biorchestra Co., Ltd. | Micellar nanoparticles and uses thereof |
| CA3218849A1 (en) * | 2021-05-14 | 2022-11-17 | University Of Rochester | Variants of sirt6 for use in preventing and/or treating age-related diseases |
| WO2022245868A1 (en) * | 2021-05-18 | 2022-11-24 | Fluent Biosciences Inc. | Perturbed genomic expression in pretemplated instant partitions |
| WO2022251445A1 (en) | 2021-05-28 | 2022-12-01 | Fluent Biosciences Inc. | Spatial transcriptomics in pips |
| US20230076395A1 (en) * | 2021-08-17 | 2023-03-09 | California Institute Of Technology | Cell-to-cell delivery of rna circuits |
| KR102775653B1 (ko) * | 2021-09-15 | 2025-03-05 | 한국기초과학지원연구원 | 아르기닌 리치 펩타이드를 포함하는 단백질 분해제 및 이를 이용한 단백질 이상질환의 예방 또는 치료용 약학적 조성물 |
| MX2024003887A (es) | 2021-10-14 | 2024-07-09 | Arsenal Biosciences Inc | Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica. |
| EP4426475A4 (en) | 2021-11-03 | 2025-12-24 | Fluent Biosciences Inc | DEVICES TO IMPROVE THE PREPARATION AND PROCESSING OF SAMPLES |
| AU2022408167A1 (en) | 2021-12-08 | 2024-06-06 | Regeneron Pharmaceuticals, Inc. | Mutant myocilin disease model and uses thereof |
| CN115304756B (zh) * | 2022-01-30 | 2023-05-09 | 上海科技大学 | 一种五元脂质纳米颗粒及其制备方法和应用 |
| CN114480672B (zh) * | 2022-02-22 | 2023-08-15 | 青岛农业大学 | 一种通过miR-145筛选高产肉率碱地黑牛的方法 |
| CN114933658B (zh) * | 2022-04-24 | 2023-07-11 | 深圳市鹏泰生物科技有限公司 | 一种短肽元件及其应用方法 |
| CN115184480B (zh) * | 2022-05-24 | 2024-07-09 | 南京中医药大学 | 一种用于鉴定华蟾素制剂或蟾皮的特征多肽及其含量测定方法与应用 |
| CN115177734B (zh) * | 2022-07-05 | 2025-03-14 | 中国人民解放军空军军医大学 | 一种靶向干预线粒体基因表达的工程化外泌体及其构建方法和应用 |
| CN115350330B (zh) * | 2022-09-01 | 2023-10-20 | 北京化工大学 | 一种负电性小分子调控的表面在蛋白差异性黏附上的应用 |
| US12534721B2 (en) | 2022-10-06 | 2026-01-27 | Illumina, Inc. | Quantitative detection and analysis of moleculesip |
| WO2024098238A1 (en) * | 2022-11-08 | 2024-05-16 | Pulsar Therapeutics Inc. | Methods for treating hemoglobinopathies |
| WO2025049677A1 (en) * | 2023-08-31 | 2025-03-06 | Tufts Medical Center, Inc. | Use of nanoparticles in therapeutic and imaging methods |
| AU2024367190A1 (en) * | 2023-10-23 | 2026-04-23 | The Board Of Regents Of The University Of Texas System | Novel endoplasmic reticulum targeting signal peptides and uses thereof |
| CN117599200A (zh) * | 2023-10-27 | 2024-02-27 | 华中科技大学 | 一种新型的双链rna递送载体及应用 |
| CN122477215A (zh) * | 2023-11-09 | 2026-07-28 | 得克萨斯州大学系统董事会 | 内源性突触靶向信号肽及其用途 |
| WO2025207378A1 (en) * | 2024-03-25 | 2025-10-02 | Massachusetts Institute Of Technology | Scalable and high throughput assembly of layer-by-layer nanoparticles |
| KR20250160320A (ko) * | 2024-05-03 | 2025-11-12 | 한양대학교 산학협력단 | 엔도좀 탈출 효율이 향상된 항 인간 트랜스페린 수용체 항체, 및 이를 이용한 다중특이적 항체 및 약학 조성물 |
| WO2026117631A2 (en) | 2024-11-26 | 2026-06-04 | City Therapeutics, Inc. | Factor xi rnai agent compositions and methods of use thereof |
| WO2026152164A1 (en) | 2025-01-13 | 2026-07-16 | Sail Biomedicines, Inc. | Cd5-targeted lipid nanoparticles encapsulating polyribonucleotides encoding chimeric antigen receptors, and methods to generate car-expressing t cells in vivo |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US6051429A (en) | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
| US6379966B2 (en) | 1999-02-26 | 2002-04-30 | Mirus Corporation | Intravascular delivery of non-viral nucleic acid |
| KR100535258B1 (ko) | 1997-10-29 | 2005-12-09 | 도레이 카부시키가이샤 | 생분해성 및 발포성을 갖는 수지 조성물 |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
| BR0010705A (pt) | 1999-04-30 | 2002-02-05 | Amylin Pharmaceuticals Inc | Exendinas modificadas e agonistas da exendina |
| US7098032B2 (en) | 2001-01-02 | 2006-08-29 | Mirus Bio Corporation | Compositions and methods for drug delivery using pH sensitive molecules |
| AU2001257331A1 (en) | 2000-04-28 | 2001-11-12 | Sangamo Biosciences, Inc. | Methods for designing exogenous regulatory molecules |
| US7355019B2 (en) | 2000-06-06 | 2008-04-08 | Sibtech, Inc. | Cysteine-containing peptide tag for site-specific conjugation of proteins |
| US20030082561A1 (en) | 2000-07-21 | 2003-05-01 | Takashi Sera | Zinc finger domain recognition code and uses thereof |
| US20030138453A1 (en) | 2000-09-28 | 2003-07-24 | O'hagan Derek | Microparticles for delivery of heterologous nucleic acids |
| SI1724284T1 (sl) | 2000-12-07 | 2009-12-31 | Lilly Co Eli | Glp-1 fuzijski proteini |
| US7273923B2 (en) | 2001-01-22 | 2007-09-25 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
| GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
| US20040102606A1 (en) | 2001-04-24 | 2004-05-27 | Danuta Balicki | Histone H2A -derived peptides useful in gene delivery |
| US6805904B2 (en) | 2002-02-20 | 2004-10-19 | International Business Machines Corporation | Process of forming a multilayer nanoparticle-containing thin film self-assembly |
| EP1504092B2 (en) | 2002-03-21 | 2014-06-25 | Sangamo BioSciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| EP1499895B1 (en) | 2002-04-22 | 2008-05-07 | University Of Florida | Functionalized nanoparticles and methods of use |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| WO2004085998A2 (en) | 2003-03-28 | 2004-10-07 | The Children's Hospital Of Philadelphia | Biomimetic hierarchies using functionalized nanoparticles as building blocks |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| EP2927318B1 (en) | 2003-08-08 | 2020-05-20 | Sangamo Therapeutics, Inc. | Methods and compositions for targeted cleavage and recombination |
| US20050053668A1 (en) | 2003-08-21 | 2005-03-10 | Southwest Research Institute | Skeletally targeted nanoparticles |
| EP1748796A4 (en) | 2004-03-05 | 2008-08-27 | Univ Texas | MULTILAYER NANOMEDICINE DELIVERY SYSTEM AND METHOD |
| DK1771206T3 (en) | 2004-05-05 | 2018-05-22 | Silence Therapeutics Gmbh | LIPIDS, LIPID COMPLEXES AND USE THEREOF |
| WO2005123142A1 (en) | 2004-06-10 | 2005-12-29 | Abraxis Bioscience, Inc. | A method using inorganic nanoparticles as non-viral vectors for gene therapy |
| US20060088599A1 (en) | 2004-08-02 | 2006-04-27 | Prasad Paras N | Amino functionalized ORMOSIL nanoparticles as delivery vehicles |
| US20090220587A1 (en) * | 2005-02-01 | 2009-09-03 | United State Army | Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands |
| AU2007227202B2 (en) | 2006-03-21 | 2013-08-22 | Amylin Pharmaceuticals, Llc | Peptide-peptidase inhibitor conjugates and methods of using same |
| SI2019683T2 (sl) | 2006-04-25 | 2022-10-28 | The Regents Of The University Of California | Dajanje rastnih faktorjev za zdravljenje motenj CŽS |
| US7928186B2 (en) * | 2006-08-02 | 2011-04-19 | Phoenix Pharmaceuticals, Inc. | Cell permeable bioactive peptide conjugates |
| JP2010500029A (ja) | 2006-08-11 | 2010-01-07 | ダウ アグロサイエンシィズ エルエルシー | ジンクフィンガーヌクレアーゼ媒介相同組換え |
| WO2008103276A2 (en) | 2007-02-16 | 2008-08-28 | Merck & Co., Inc. | Compositions and methods for potentiated activity of biologicaly active molecules |
| US20100196492A1 (en) | 2007-03-08 | 2010-08-05 | Green Jordan J | Electrostatic coating of particles for drug delivery |
| TWI428135B (zh) | 2007-03-26 | 2014-03-01 | Hirofumi Takeuchi | And a carrier composition for quick-acting nucleic acid delivery |
| AU2008305590A1 (en) | 2007-09-27 | 2009-04-02 | Sangamo Therapeutics, Inc. | Genomic editing in zebrafish using zinc finger nucleases |
| EP2597155B1 (en) | 2007-10-25 | 2016-11-23 | Sangamo BioSciences, Inc. | Methods and compositions for targeted integration |
| US8389485B2 (en) | 2007-10-29 | 2013-03-05 | University Of Massachusetts | Encapsulated nanoparticles for nucleic acid delivery |
| WO2009059309A2 (en) | 2007-11-01 | 2009-05-07 | Panacea Pharmaceuticals, Inc. | Furin-cleavable peptide linkers for drug-ligand conjugates |
| US8323618B2 (en) | 2007-11-07 | 2012-12-04 | University Of Houston System | Ultrasmall superparamagnetic iron oxide nanoparticles and uses thereof |
| CN101970687A (zh) | 2007-11-09 | 2011-02-09 | 东北大学 | 用于体内基因输送的自组装胶束样纳米颗粒 |
| GB0725321D0 (en) | 2007-12-31 | 2008-02-06 | Syntaxin Ltd | Delivery vehicles |
| US7999025B2 (en) | 2008-01-28 | 2011-08-16 | University Of Utah Research Foundation | Asymmetrically-functionalized nanoparticles organized on one-dimensional chains |
| US8344116B2 (en) * | 2008-03-17 | 2013-01-01 | Case Western Reserve University | Polymers and complexes for delivery of nucleic acids to intracellular targets |
| US8324333B2 (en) | 2008-06-05 | 2012-12-04 | Wisconsin Alumni Research Foundation | Anionic charge-dynamic polymers for release of cationic agents |
| US8404636B2 (en) * | 2008-07-17 | 2013-03-26 | George Mason Intellectual Properties, Inc. | Targeted delivery of antimicrobial agents |
| CA2739608A1 (en) * | 2008-10-07 | 2010-04-15 | The Regents Of The University Of California | Recombinant nell protein production |
| EP3699172A3 (en) | 2008-11-10 | 2020-11-18 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
| EP3156494B8 (en) | 2008-12-04 | 2018-09-19 | Sangamo Therapeutics, Inc. | Genome editing in rats using zinc-finger nucleases |
| CA2757831C (en) | 2009-04-07 | 2017-09-26 | Dow Agrosciences Llc | Nanoparticle mediated delivery of sequence specific nucleases |
| WO2011000095A1 (en) * | 2009-07-02 | 2011-01-06 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
| US20110077581A1 (en) * | 2009-09-25 | 2011-03-31 | Georgia Tech Research Corporation | Targeted cellular delivery of nanoparticles |
| KR20120092611A (ko) | 2009-09-30 | 2012-08-21 | 글락소 그룹 리미티드 | 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트 |
| WO2011041897A1 (en) * | 2009-10-06 | 2011-04-14 | Angiochem Inc. | Compositions and methods for the transport of therapeutic agents |
| PT2816112T (pt) | 2009-12-10 | 2018-11-20 | Univ Iowa State Res Found Inc | Modificação do adn modificada pelo efector tal |
| WO2011096408A1 (ja) | 2010-02-02 | 2011-08-11 | 国立大学法人 東京大学 | 複合体微粒子およびその製造方法、ならびに該複合体微粒子を用いた薬学組成物 |
| KR101198715B1 (ko) | 2010-05-14 | 2012-11-13 | 한국생명공학연구원 | 핵산 및 친수성 음이온 화합물의 고효율 포획을 위한 비대칭 리포솜 및 이의 제조방법 |
| WO2012012352A2 (en) * | 2010-07-19 | 2012-01-26 | Amidebio, Llc | Modified peptides and proteins |
| WO2012092339A2 (en) * | 2010-12-28 | 2012-07-05 | The Children's Hospital Of Philadelphia | The design of hydrolytically releasable prodrugs for sustained release nanoparticle formulations |
| US9074187B2 (en) | 2011-03-21 | 2015-07-07 | Board Of Trustees Of The University Of Arkansas | Nanostructural materials that increase mineralization in bone cells and affect gene expression through miRNA regulation and applications of same |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US20140115726A1 (en) | 2011-04-05 | 2014-04-24 | Cellectis | New tale-protein scaffolds and uses thereof |
| CA2834375C (en) | 2011-04-27 | 2020-07-14 | Amyris, Inc. | Methods for genomic modification |
| US8916696B2 (en) | 2011-06-12 | 2014-12-23 | City Of Hope | Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use |
| WO2013058812A1 (en) * | 2011-10-19 | 2013-04-25 | President And Fellows Of Harvard College | Targeted delivery to pancreatic islet endothelial cells |
| US8450107B1 (en) | 2011-11-30 | 2013-05-28 | The Broad Institute Inc. | Nucleotide-specific recognition sequences for designer TAL effectors |
| CZ201220A3 (cs) | 2012-01-13 | 2013-07-17 | Ústav organické chemie a biochemie Akademie ved CR, v.v.i. | Lipopolyaminy sperminového typu pro konstrukci liposomálních transfekcních systému |
| EP2841056A4 (en) | 2012-04-23 | 2015-09-16 | Massachusetts Inst Technology | STABLE LAYER COATED PARTICLES |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| TR201816986T4 (tr) | 2012-06-08 | 2019-01-21 | Nitto Denko Corp | Terapötik ajan iletim formülasyonlarına yönelik lipitler. |
| EP2863892B1 (en) | 2012-06-20 | 2017-11-08 | University Of Waterloo | Mucoadhesive nanoparticle delivery system |
| EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| KR102955556B1 (ko) | 2012-12-12 | 2026-04-22 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물 |
| CN105209621B (zh) | 2012-12-12 | 2021-05-25 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| SG10201707569YA (en) | 2012-12-12 | 2017-10-30 | Broad Inst Inc | Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| PT2931898E (pt) | 2012-12-12 | 2016-06-16 | Harvard College | Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais |
| MX380562B (es) | 2012-12-12 | 2025-03-12 | Broad Inst Inc | Modificaciones de sistemas, métodos y composiciones guía optimizadas para la manipulación de secuencias. |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| EP3064585B1 (en) | 2012-12-12 | 2020-02-05 | The Broad Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
| CA2893579A1 (en) | 2012-12-13 | 2014-06-19 | Dow Agrosciences Llc | Dna detection methods for site specific nuclease activity |
| IL308158A (en) | 2012-12-17 | 2023-12-01 | Harvard College | Rna-guided human genome engineering |
| US10227610B2 (en) | 2013-02-25 | 2019-03-12 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
| US9504747B2 (en) | 2013-03-08 | 2016-11-29 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| PL2970463T3 (pl) * | 2013-03-13 | 2018-04-30 | Biocrine Ab | Sposoby leczenia i/lub ograniczania rozwoju cukrzycy |
| ES2749624T3 (es) | 2013-03-14 | 2020-03-23 | Caribou Biosciences Inc | Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| CN105408483A (zh) | 2013-03-15 | 2016-03-16 | 通用医疗公司 | 遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向 |
| JP2016512048A (ja) | 2013-03-15 | 2016-04-25 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | CRISPR/Casシステムを使用した植物ゲノム操作 |
| US20140273230A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
| US20140349400A1 (en) | 2013-03-15 | 2014-11-27 | Massachusetts Institute Of Technology | Programmable Modification of DNA |
| US11332719B2 (en) | 2013-03-15 | 2022-05-17 | The Broad Institute, Inc. | Recombinant virus and preparations thereof |
| US10760064B2 (en) | 2013-03-15 | 2020-09-01 | The General Hospital Corporation | RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci |
| US20140364333A1 (en) | 2013-03-15 | 2014-12-11 | President And Fellows Of Harvard College | Methods for Live Imaging of Cells |
| CN105263312A (zh) | 2013-04-05 | 2016-01-20 | 美国陶氏益农公司 | 用于在植物基因组内整合外源序列的方法和组合物 |
| DK3456831T3 (da) | 2013-04-16 | 2021-09-06 | Regeneron Pharma | Målrettet modifikation af rottegenom |
| US10604771B2 (en) | 2013-05-10 | 2020-03-31 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| US20140349405A1 (en) | 2013-05-22 | 2014-11-27 | Wisconsin Alumni Research Foundation | Rna-directed dna cleavage and gene editing by cas9 enzyme from neisseria meningitidis |
| US9873907B2 (en) | 2013-05-29 | 2018-01-23 | Agilent Technologies, Inc. | Method for fragmenting genomic DNA using CAS9 |
| EP3603679B1 (en) | 2013-06-04 | 2022-08-10 | President and Fellows of Harvard College | Rna-guided transcriptional regulation |
| PT3049116T (pt) * | 2013-09-23 | 2019-04-03 | Rensselaer Polytech Inst | Distribuição genética mediada por nanopartículas, edição genómica e modificação direcionada a ligantes em várias populações celulares |
| WO2015048577A2 (en) | 2013-09-27 | 2015-04-02 | Editas Medicine, Inc. | Crispr-related methods and compositions |
| PL3057604T3 (pl) | 2013-10-14 | 2021-12-20 | Nanosphere Health Sciences Inc. | Kompozycje nanocząstek i sposoby jako nośniki czynników nutraceutycznych przez błony komórkowe i bariery biologiczne |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| WO2015089419A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
| CN107073028A (zh) | 2013-12-13 | 2017-08-18 | 南洋理工大学 | 多层纳米颗粒及其制作方法和使用方法 |
| EP3148583B1 (en) * | 2014-06-02 | 2020-04-29 | Li-Cor, Inc. | Phthalocyanine probes and uses thereof |
| DK3221293T3 (da) | 2014-11-18 | 2023-04-03 | Arcturus Therapeutics Inc | Ioniserbar kationisk lipid til RNA-afgivelse |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
-
2017
- 2017-12-14 RU RU2019121801A patent/RU2019121801A/ru unknown
- 2017-12-14 JP JP2019531758A patent/JP2020502124A/ja active Pending
- 2017-12-14 KR KR1020247006016A patent/KR20240027888A/ko active Pending
- 2017-12-14 KR KR1020197020171A patent/KR102641844B1/ko active Active
- 2017-12-14 CA CA3045131A patent/CA3045131A1/en not_active Abandoned
- 2017-12-14 CN CN201780084854.4A patent/CN110582302A/zh active Pending
- 2017-12-14 IL IL267034A patent/IL267034B2/en unknown
- 2017-12-14 JP JP2019531743A patent/JP7317706B2/ja active Active
- 2017-12-14 US US15/842,820 patent/US10975388B2/en active Active
- 2017-12-14 WO PCT/US2017/066541 patent/WO2018112278A1/en not_active Ceased
- 2017-12-14 EP EP17881690.6A patent/EP3554555A4/en active Pending
- 2017-12-14 US US15/842,829 patent/US20180179553A1/en not_active Abandoned
- 2017-12-14 IL IL267033A patent/IL267033B2/en unknown
- 2017-12-14 RU RU2019121992A patent/RU2019121992A/ru unknown
- 2017-12-14 KR KR1020197020175A patent/KR20210035022A/ko not_active Ceased
- 2017-12-14 WO PCT/US2017/066545 patent/WO2018112282A1/en not_active Ceased
- 2017-12-14 AU AU2017378431A patent/AU2017378431A1/en not_active Abandoned
- 2017-12-14 CN CN201780085854.6A patent/CN110582301A/zh active Pending
- 2017-12-14 CA CA3045134A patent/CA3045134A1/en active Pending
- 2017-12-14 AU AU2017378427A patent/AU2017378427A1/en not_active Abandoned
- 2017-12-14 EP EP17882004.9A patent/EP3554546A4/en not_active Withdrawn
- 2017-12-14 KR KR1020247039185A patent/KR20240172763A/ko active Pending
-
2019
- 2019-12-02 US US16/701,014 patent/US20200095605A1/en active Pending
-
2020
- 2020-11-25 US US17/104,552 patent/US12123012B2/en active Active
-
2023
- 2023-03-02 JP JP2023031534A patent/JP2023071853A/ja active Pending
- 2023-07-19 JP JP2023117292A patent/JP2023134730A/ja active Pending
- 2023-08-29 US US18/458,076 patent/US20240026375A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019121801A3 (cg-RX-API-DMAC7.html) | ||
| BR112018068177A2 (cg-RX-API-DMAC7.html) | ||
| BR112019002665A2 (cg-RX-API-DMAC7.html) | ||
| BR112018004986A2 (cg-RX-API-DMAC7.html) | ||
| BR112019001429A2 (cg-RX-API-DMAC7.html) | ||
| BR112019008318A2 (cg-RX-API-DMAC7.html) | ||
| BR112019008315A2 (cg-RX-API-DMAC7.html) | ||
| BR212018070320U2 (cg-RX-API-DMAC7.html) | ||
| BR112019008501B1 (pt) | Método realizado por um equipamento de usuário, método realizado por um nó de rede, equipamento de usuário, nó de rede, e, meios de armazenamento legíveis por computador | |
| BR112019003116B1 (pt) | Configuração de símbolo de rajada comum de uplink | |
| BR112019002215B1 (pt) | Seleção de nível de melhoramento de cobertura baseada em classe de potência | |
| BR112018075550B1 (pt) | Método para reparo de arquivo de intervalo de bytes, dispositivo de computação e memória | |
| BR112018076493B1 (pt) | Sistemas e métodos para detecção de posição de feixe de luz | |
| BR112018073794B1 (pt) | Partícula, método de geração da partícula, vacina ou composição farmacêutica | |
| BR112018073322B1 (pt) | Método para comunicação sem fio realizado por um equipamento de usuário (ue), método para comunicação sem fio realizado por uma estação base (bs), aparelho para comunicações sem fio, e, memória legível por computador | |
| BR122023000741B1 (pt) | Uso de anticorpos anti-il-1r3 humanizados, fragmento ou derivado do mesmo na fabricação de uma composição farmacêutica para tratamento de uma doença mediada por il-1r3 | |
| BR122026002520A2 (pt) | Célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, sistema, método, e, método para produção de uma proteína de ligação a antígeno | |
| BR112019006736A2 (cg-RX-API-DMAC7.html) | ||
| CN303635875S (zh) | 排气扇(1) | |
| CN303633785S (zh) | 压力式温度表仿真校验台(fzxy—ⅰ型) | |
| CN303536579S (zh) | 婴儿用品收纳盒 | |
| CN303579318S (zh) | 用于手机的图形用户界面 | |
| CN303536645S (zh) | 牙刷(Cosy) | |
| CN303536045S (zh) | 嫁衣(15) | |
| CN303536111S (zh) | 眼罩(条纹) |